Drug Trial Radar · NCT07490262
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Mar 27, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experienced disease progression following prior surgical resection or local therapy.
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
BevacizumabBiological
15 mg/kg intravenous infusion, administered on Day 1 of each 3-week treatment cycle
CapecitabineDrug
1000 mg/m² orally, administered on Days 1-14 of each 3-week treatment cycle, maximum 4 cycles.
OxaliplatinDrug
85 mg/m² intravenous infusion, administered on Day 1 of each 3-week treatment cycle, maximum 4 cycles.
IBI310Biological
1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle
SintilimabBiological
200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II: ORR (Objective Response Rate) assessed by investigator per RECIST 1.1.Time frame: up to 2 years
- Phase II: PFS(Progression-Free Survival) assessed by investigator per RECIST 1.1.Time frame: up to 2 years
- Phase II: AEs(Adverse Event)Time frame: up to 2 years
- Phase II: TRAES(Treatment Emergent Adverse Event)Time frame: up to 2 years
- Phase II: SAEs(Serious Adverse Event)Time frame: up to 2 years
- Phase III: OS(Overall Survival)Time frame: up to 2 years
- Phase III: PFS(Progression-Free Survival)assessed by the Independent Radiologic Review Committee (IRRC) per RECIST 1.1.Time frame: up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hosptial of USTC
Hefei, Anhui, China · Recruiting
Zhongshan Hospital, Fudan university
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.